FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2883995364> ?p ?o ?g. }

• W2883995364 endingPage "2270" @default.
• W2883995364 startingPage "2265" @default.
• W2883995364 abstract "Allogeneic stem cell transplantation is an alternative for patients with relapsed or refractory Hodgkin lymphoma (HL), but only limited data on unrelated umbilical cord blood transplantation (UCBT) are available. We analyzed 131 adults with HL who underwent UCBT in European Society for Blood and Marrow Transplantation centers from 2003 to 2015. Disease status at UCBT was complete remission (CR) in 59 patients (47%), and almost all patients had received a previous autologous stem cell transplantation. The 4-year progression-free survival (PFS) and overall survival (OS) were 26% (95% confidence interval [CI], 19% to 34%) and 46% (95% CI, 37% to 55%), respectively. Relapse incidence was 44% (95% CI, 36% to 54%), and nonrelapse mortality (NRM) was 31% (95% CI, 23% to 40%) at 4 years. In multivariate analysis refractory/relapsed disease status at UCBT was associated with increased relapse incidence (hazard ratio [HR], 3.14 [95% CI, 1.41 to 7.00], P = .005) and NRM (HR, 3.61 [95% CI, 1.58 to 8.27], P = .002) and lower PFS (HR, 3.45 [95% CI, 1.95 to 6.10], P < .001) and OS (HR, 3.10 [95% CI, 1.60 to 5.99], P = .001). Conditioning regimen with cyclophosphamide + fludarabine + 2 Gy total body irradiation (Cy+Flu+2GyTBI) was associated with decreased risk of NRM (HR, .26 [95% CI, .10 to .64], P = .004). Moreover, Cy+Flu+2GyTBI conditioning regimen was associated with a better OS (HR, .25 [95% CI, .12 to .50], P < .001) and PFS (HR, .51 [95% CI, .27 to .96], P = .04). UCBT is feasible in heavily pretreated patients with HL. The reduced-intensity conditioning regimen with Cy+Flu+2GyTBI is associated with a better OS and NRM. However, outcomes are poor in patients not in CR at UCBT." @default.
• W2883995364 created "2018-08-03" @default.
• W2883995364 creator A5007202804 @default.
• W2883995364 creator A5008706897 @default.
• W2883995364 creator A5011180142 @default.
• W2883995364 creator A5019979915 @default.
• W2883995364 creator A5022161221 @default.
• W2883995364 creator A5025494836 @default.
• W2883995364 creator A5028727344 @default.
• W2883995364 creator A5028816601 @default.
• W2883995364 creator A5029475017 @default.
• W2883995364 creator A5034473496 @default.
• W2883995364 creator A5034779401 @default.
• W2883995364 creator A5036122955 @default.
• W2883995364 creator A5036207495 @default.
• W2883995364 creator A5038588053 @default.
• W2883995364 creator A5038747590 @default.
• W2883995364 creator A5039928717 @default.
• W2883995364 creator A5040100217 @default.
• W2883995364 creator A5042417187 @default.
• W2883995364 creator A5045381644 @default.
• W2883995364 creator A5049735878 @default.
• W2883995364 creator A5050692336 @default.
• W2883995364 creator A5053474378 @default.
• W2883995364 creator A5058925624 @default.
• W2883995364 creator A5060896204 @default.
• W2883995364 creator A5076762639 @default.
• W2883995364 creator A5079498223 @default.
• W2883995364 creator A5082453515 @default.
• W2883995364 creator A5086577784 @default.
• W2883995364 creator A5088899895 @default.
• W2883995364 date "2018-11-01" @default.
• W2883995364 modified "2023-10-18" @default.
• W2883995364 title "Outcomes of Advanced Hodgkin Lymphoma after Umbilical Cord Blood Transplantation: A Eurocord and EBMT Lymphoma and Cellular Therapy & Immunobiology Working Party Study" @default.
• W2883995364 cites W1491627120 @default.
• W2883995364 cites W1860199933 @default.
• W2883995364 cites W1971984984 @default.
• W2883995364 cites W1972484609 @default.
• W2883995364 cites W1975053754 @default.
• W2883995364 cites W1988531571 @default.
• W2883995364 cites W2011118089 @default.
• W2883995364 cites W2011561948 @default.
• W2883995364 cites W2023237036 @default.
• W2883995364 cites W2030225848 @default.
• W2883995364 cites W2052220490 @default.
• W2883995364 cites W2053278212 @default.
• W2883995364 cites W2062486240 @default.
• W2883995364 cites W2065370859 @default.
• W2883995364 cites W2111613096 @default.
• W2883995364 cites W2118805549 @default.
• W2883995364 cites W2122473065 @default.
• W2883995364 cites W2125616358 @default.
• W2883995364 cites W2149997323 @default.
• W2883995364 cites W2155256323 @default.
• W2883995364 cites W2169752761 @default.
• W2883995364 cites W2169944840 @default.
• W2883995364 cites W2178245852 @default.
• W2883995364 cites W2504623699 @default.
• W2883995364 cites W2567998110 @default.
• W2883995364 cites W2570383534 @default.
• W2883995364 cites W2576236969 @default.
• W2883995364 cites W2731673561 @default.
• W2883995364 cites W2767483264 @default.
• W2883995364 cites W2769732646 @default.
• W2883995364 cites W2776736524 @default.
• W2883995364 cites W2790139823 @default.
• W2883995364 cites W2791231722 @default.
• W2883995364 cites W2802434483 @default.
• W2883995364 doi "https://doi.org/10.1016/j.bbmt.2018.07.019" @default.
• W2883995364 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30031070" @default.
• W2883995364 hasPublicationYear "2018" @default.
• W2883995364 type Work @default.
• W2883995364 sameAs 2883995364 @default.
• W2883995364 citedByCount "9" @default.
• W2883995364 countsByYear W28839953642019 @default.
• W2883995364 countsByYear W28839953642020 @default.
• W2883995364 countsByYear W28839953642022 @default.
• W2883995364 countsByYear W28839953642023 @default.
• W2883995364 crossrefType "journal-article" @default.
• W2883995364 hasAuthorship W2883995364A5007202804 @default.
• W2883995364 hasAuthorship W2883995364A5008706897 @default.
• W2883995364 hasAuthorship W2883995364A5011180142 @default.
• W2883995364 hasAuthorship W2883995364A5019979915 @default.
• W2883995364 hasAuthorship W2883995364A5022161221 @default.
• W2883995364 hasAuthorship W2883995364A5025494836 @default.
• W2883995364 hasAuthorship W2883995364A5028727344 @default.
• W2883995364 hasAuthorship W2883995364A5028816601 @default.
• W2883995364 hasAuthorship W2883995364A5029475017 @default.
• W2883995364 hasAuthorship W2883995364A5034473496 @default.
• W2883995364 hasAuthorship W2883995364A5034779401 @default.
• W2883995364 hasAuthorship W2883995364A5036122955 @default.
• W2883995364 hasAuthorship W2883995364A5036207495 @default.
• W2883995364 hasAuthorship W2883995364A5038588053 @default.
• W2883995364 hasAuthorship W2883995364A5038747590 @default.
• W2883995364 hasAuthorship W2883995364A5039928717 @default.
• W2883995364 hasAuthorship W2883995364A5040100217 @default.
• W2883995364 hasAuthorship W2883995364A5042417187 @default.
• W2883995364 hasAuthorship W2883995364A5045381644 @default.

• next